Approvals can happen at any time. Knowing they have been actively sharing data with the FDA and have a EUA submission - there mere mention of therapeutics at this meeting could generate significant interest in RLFTF. We all know the FDA has been focused on vaccines and that's probably the entire meeting BUT there is that possibility.
Market Data 
Markets 
